Trade $ TalkMed - 5G3sg CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.021 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.020734% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.001184% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SGD | ||||||||
Margin | 5% | ||||||||
Stock exchange | Singapore | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.357 |
Open* | 0.357 |
1-Year Change* | -12.29% |
Day's Range* | 0.357 - 0.357 |
52 wk Range | 0.37-0.44 |
Average Volume (10 days) | 20.49K |
Average Volume (3 months) | 194.33K |
Market Cap | 497.07M |
P/E Ratio | 15.26 |
Shares Outstanding | 1.33B |
Revenue | 81.93M |
EPS | 0.02 |
Dividend (Yield %) | 6.4 |
Beta | 0.19 |
Next Earnings Date | Feb 22, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 0.357 | 0.000 | 0.00% | 0.357 | 0.357 | 0.357 |
Mar 27, 2024 | 0.357 | 0.000 | 0.00% | 0.357 | 0.357 | 0.357 |
Mar 26, 2024 | 0.357 | -0.005 | -1.38% | 0.362 | 0.362 | 0.357 |
Mar 25, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 21, 2024 | 0.362 | -0.005 | -1.36% | 0.367 | 0.367 | 0.357 |
Mar 19, 2024 | 0.357 | 0.000 | 0.00% | 0.357 | 0.362 | 0.357 |
Mar 18, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 15, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 14, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 13, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.367 | 0.362 |
Mar 12, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 11, 2024 | 0.362 | -0.005 | -1.36% | 0.367 | 0.367 | 0.362 |
Mar 8, 2024 | 0.367 | 0.005 | 1.38% | 0.362 | 0.367 | 0.362 |
Mar 7, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 6, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 5, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Mar 1, 2024 | 0.362 | 0.000 | 0.00% | 0.362 | 0.362 | 0.362 |
Feb 29, 2024 | 0.372 | 0.000 | 0.00% | 0.372 | 0.372 | 0.372 |
Feb 28, 2024 | 0.367 | 0.000 | 0.00% | 0.367 | 0.367 | 0.367 |
Feb 27, 2024 | 0.367 | -0.005 | -1.34% | 0.372 | 0.372 | 0.367 |
$ TalkMed Events
Time (UTC) | Country | Event |
---|---|---|
Friday, April 19, 2024 | ||
Time (UTC) 10:00 | Country SG
| Event Talkmed Group Ltd Annual Shareholders Meeting Talkmed Group Ltd Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 76.6 | 60.746 | 62.136 | 75.919 | 61.278 |
Revenue | 76.6 | 60.746 | 62.136 | 75.919 | 61.278 |
Total Operating Expense | 37.498 | 32.385 | 36.244 | 33.52 | 26.138 |
Selling/General/Admin. Expenses, Total | 29.994 | 26.604 | 26.536 | 25.402 | 22.909 |
Interest Expense (Income) - Net Operating | -0.672 | -0.114 | -0.472 | -1.185 | -0.982 |
Other Operating Expenses, Total | 4.993 | 4.718 | 4.766 | 5.878 | 4.211 |
Operating Income | 39.102 | 28.361 | 25.892 | 42.399 | 35.14 |
Net Income Before Taxes | 36.847 | 27.286 | 24.807 | 41.349 | 34.003 |
Net Income After Taxes | 28.991 | 21.428 | 18.517 | 32.806 | 27.214 |
Minority Interest | 1.556 | 3.687 | 4.252 | 2.945 | 1.694 |
Net Income Before Extra. Items | 30.547 | 25.115 | 22.769 | 35.751 | 28.908 |
Net Income | 30.547 | 25.115 | 22.769 | 35.751 | 28.908 |
Income Available to Common Excl. Extra. Items | 30.547 | 25.115 | 22.769 | 35.751 | 28.908 |
Income Available to Common Incl. Extra. Items | 30.547 | 25.115 | 22.769 | 35.751 | 28.908 |
Diluted Net Income | 30.547 | 25.115 | 22.769 | 35.751 | 28.908 |
Diluted Weighted Average Shares | 1329.49 | 1326.99 | 1324.25 | 1314.72 | 1314.8 |
Diluted EPS Excluding Extraordinary Items | 0.02298 | 0.01893 | 0.01719 | 0.02719 | 0.02199 |
Dividends per Share - Common Stock Primary Issue | 0.03 | 0.016 | 0.0135 | 0.023 | 0.01826 |
Diluted Normalized EPS | 0.02336 | 0.01815 | 0.01827 | 0.02719 | 0.02199 |
Interest Income (Expense), Net Non-Operating | -2.255 | -1.075 | -1.085 | -1.05 | -1.137 |
Depreciation / Amortization | 2.543 | 2.488 | 3.513 | 3.425 | |
Unusual Expense (Income) | 0.64 | -1.311 | 1.901 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 37.795 | 44.131 | 32.469 | 31.892 | 28.854 |
Revenue | 37.795 | 44.131 | 32.469 | 31.892 | 28.854 |
Total Operating Expense | 20.379 | 20.514 | 16.984 | 16.414 | 15.971 |
Selling/General/Admin. Expenses, Total | 15.624 | 16.341 | 13.653 | 13.987 | 12.617 |
Depreciation / Amortization | 1.366 | 1.265 | 1.278 | 1.289 | 1.199 |
Interest Expense (Income) - Net Operating | -0.893 | -0.638 | -0.034 | -0.095 | -0.019 |
Other Operating Expenses, Total | 3.828 | 2.906 | 2.087 | 1.233 | 2.174 |
Operating Income | 17.416 | 23.617 | 15.485 | 15.478 | 12.883 |
Interest Income (Expense), Net Non-Operating | -1.003 | -1.386 | -0.869 | -0.719 | -0.356 |
Net Income Before Taxes | 16.413 | 22.231 | 14.616 | 14.759 | 12.527 |
Net Income After Taxes | 12.489 | 17.542 | 11.449 | 11.694 | 9.734 |
Minority Interest | 1.783 | 0.875 | 0.681 | 2.611 | 1.076 |
Net Income Before Extra. Items | 14.272 | 18.417 | 12.13 | 14.305 | 10.81 |
Net Income | 14.272 | 18.417 | 12.13 | 14.305 | 10.81 |
Income Available to Common Excl. Extra. Items | 14.272 | 18.417 | 12.13 | 14.305 | 10.81 |
Income Available to Common Incl. Extra. Items | 14.272 | 18.417 | 12.13 | 14.305 | 10.81 |
Diluted Net Income | 14.272 | 18.417 | 12.13 | 14.305 | 10.81 |
Diluted Weighted Average Shares | 1331.55 | 1330.02 | 1328.96 | 1327.46 | 1326.52 |
Diluted EPS Excluding Extraordinary Items | 0.01072 | 0.01385 | 0.00913 | 0.01078 | 0.00815 |
Dividends per Share - Common Stock Primary Issue | 0.009 | 0.015 | 0.015 | 0.009 | 0.007 |
Diluted Normalized EPS | 0.01098 | 0.01423 | 0.00913 | 0.01078 | 0.00815 |
Unusual Expense (Income) | 0.454 | 0.64 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 94.782 | 92.424 | 91.313 | 94.431 | 83.637 |
Cash and Short Term Investments | 81.241 | 82.164 | 79.43 | 80.698 | 73.993 |
Cash | 22.494 | 15.258 | 10.132 | 18.373 | 13.421 |
Short Term Investments | 58.747 | 66.906 | 69.298 | 62.325 | 60.572 |
Total Receivables, Net | 11.822 | 9.002 | 10.295 | 12.267 | 8.714 |
Accounts Receivable - Trade, Net | 11.016 | 8.365 | 9.503 | 11.422 | 8.307 |
Total Inventory | 1.275 | 0.772 | 1.004 | 0.856 | 0.282 |
Prepaid Expenses | 0.444 | 0.486 | 0.584 | 0.61 | 0.648 |
Total Assets | 109.166 | 108.785 | 104.62 | 106.075 | 91.272 |
Property/Plant/Equipment, Total - Net | 10.082 | 8.514 | 6.172 | 8.739 | 4.227 |
Property/Plant/Equipment, Total - Gross | 17.163 | 15.135 | 13.724 | 11.461 | 5.485 |
Accumulated Depreciation, Total | -7.081 | -6.621 | -7.552 | -2.722 | -1.258 |
Long Term Investments | 3.696 | 7.437 | 7.11 | 2.887 | 3.404 |
Note Receivable - Long Term | 0.606 | 0.41 | |||
Total Current Liabilities | 19.383 | 14.245 | 17.411 | 16.768 | 12.735 |
Accounts Payable | 0.804 | 0.628 | 0.402 | 1.284 | 0.522 |
Accrued Expenses | 4.684 | 3.397 | 4.152 | 3.353 | 3.935 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 12.044 | 8.245 | 11.071 | 10.357 | 8.278 |
Total Liabilities | 20.452 | 18.607 | 21.186 | 22.97 | 17.506 |
Total Long Term Debt | 2.552 | 4.493 | 2.69 | 2.119 | 0 |
Minority Interest | -4.165 | -2.678 | -4.679 | -1.414 | -0.415 |
Other Liabilities, Total | 2.682 | 2.547 | 5.764 | 5.497 | 5.186 |
Total Equity | 88.714 | 90.178 | 83.434 | 83.105 | 73.766 |
Common Stock | 25.119 | 24.505 | 23.905 | 22.438 | 22.273 |
Retained Earnings (Accumulated Deficit) | 63.743 | 65.109 | 59.316 | 60.957 | 51.988 |
Total Liabilities & Shareholders’ Equity | 109.166 | 108.785 | 104.62 | 106.075 | 91.272 |
Total Common Shares Outstanding | 1322.55 | 1320.11 | 1318.05 | 1314.5 | 1314.29 |
Other Long Term Assets, Total | 0 | 0.025 | 0.018 | 0.004 | |
Other Equity, Total | -0.148 | 0.564 | 0.213 | -0.29 | -0.495 |
Current Port. of LT Debt/Capital Leases | 1.851 | 1.975 | 1.786 | 1.774 | |
Capital Lease Obligations | 2.552 | 4.493 | 2.69 | 2.119 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total Current Assets | 92.43 | 94.782 | 93.873 | 92.424 | 89.516 |
Cash and Short Term Investments | 81.588 | 81.241 | 83.746 | 82.164 | 80.945 |
Cash & Equivalents | 81.074 | 80.588 | 83.746 | 82.164 | 80.945 |
Total Receivables, Net | 9.323 | 11.822 | 8.745 | 9.002 | 7.064 |
Accounts Receivable - Trade, Net | 9.323 | 11.822 | 8.745 | 9.002 | 7.064 |
Total Inventory | 1.208 | 1.275 | 0.927 | 0.772 | 1.047 |
Prepaid Expenses | 0.311 | 0.444 | 0.455 | 0.486 | 0.46 |
Total Assets | 105.776 | 109.166 | 108.024 | 108.785 | 101.839 |
Property/Plant/Equipment, Total - Net | 10.277 | 10.082 | 7.252 | 8.514 | 5.394 |
Long Term Investments | 2.693 | 3.696 | 6.654 | 7.437 | 6.892 |
Other Long Term Assets, Total | 0 | 0.037 | |||
Total Current Liabilities | 23.023 | 19.383 | 14.617 | 14.245 | 13.015 |
Accounts Payable | 4.538 | 2.867 | 2.253 | 2.17 | 2.204 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.876 | 1.851 | 2.001 | 1.975 | 1.161 |
Other Current Liabilities, Total | 16.609 | 14.665 | 10.363 | 10.1 | 9.65 |
Total Liabilities | 22.47 | 20.452 | 17.423 | 18.607 | 17.044 |
Total Long Term Debt | 2.619 | 2.552 | 3.514 | 4.493 | 2.244 |
Capital Lease Obligations | 2.619 | 2.552 | 3.514 | 4.493 | 2.244 |
Minority Interest | -5.913 | -4.165 | -3.323 | -2.678 | -0.829 |
Other Liabilities, Total | 2.741 | 2.682 | 2.615 | 2.547 | 2.614 |
Total Equity | 83.306 | 88.714 | 90.601 | 90.178 | 84.795 |
Common Stock | 25.572 | 25.119 | 24.997 | 24.505 | 24.505 |
Retained Earnings (Accumulated Deficit) | 57.934 | 63.743 | 65.074 | 65.109 | 59.865 |
Other Equity, Total | -0.2 | -0.148 | 0.53 | 0.564 | 0.425 |
Total Liabilities & Shareholders’ Equity | 105.776 | 109.166 | 108.024 | 108.785 | 101.839 |
Total Common Shares Outstanding | 1324.5 | 1322.55 | 1322.05 | 1320.11 | 1320.11 |
Note Receivable - Long Term | 0.376 | 0.606 | 0.245 | 0.41 | |
Short Term Investments | 0.514 | 0.653 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 36.847 | 27.286 | 24.807 | 41.349 | 34.003 |
Cash From Operating Activities | 37.291 | 23.158 | 31.273 | 35.883 | 30.079 |
Cash From Operating Activities | 2.543 | 2.488 | 3.513 | 3.425 | 0.376 |
Non-Cash Items | 2.999 | 0.776 | 6.316 | 0.272 | 0.819 |
Cash Taxes Paid | 5.888 | 9.101 | 5.713 | 6.77 | 7.34 |
Changes in Working Capital | -5.098 | -7.392 | -3.363 | -9.163 | -5.119 |
Cash From Investing Activities | -5.012 | -1.977 | -8.446 | -2.003 | -3.929 |
Capital Expenditures | -4.326 | -0.77 | -1.954 | -2.128 | -3.929 |
Other Investing Cash Flow Items, Total | -0.686 | -1.207 | -6.492 | 0.125 | |
Cash From Financing Activities | -33.855 | -18.447 | -24.095 | -27.175 | -23.208 |
Financing Cash Flow Items | 0 | 2.8 | 2.51 | 1.883 | 4.8 |
Total Cash Dividends Paid | -31.729 | -19.141 | -25.042 | -27.142 | -28.008 |
Net Change in Cash | -1.576 | 2.734 | -1.268 | 6.705 | 2.942 |
Cash Interest Paid | 0.211 | 0.219 | 0.237 | 0.122 | |
Issuance (Retirement) of Debt, Net | -2.126 | -2.106 | -1.563 | -1.916 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | Dec 2020 | |
---|---|---|---|---|---|
Net income/Starting Line | 36.847 | 14.616 | 27.286 | 12.527 | 24.807 |
Cash From Operating Activities | 37.291 | 14.574 | 23.158 | 11.307 | 31.273 |
Cash From Operating Activities | 2.543 | 1.278 | 2.488 | 1.199 | 3.513 |
Non-Cash Items | 2.999 | 1.169 | 0.776 | 0.802 | 6.316 |
Cash Taxes Paid | 5.888 | 2.944 | 9.101 | 5.962 | 5.713 |
Cash Interest Paid | 0.211 | 0.114 | 0.219 | 0.119 | 0.237 |
Changes in Working Capital | -5.098 | -2.489 | -7.392 | -3.221 | -3.363 |
Cash From Investing Activities | -5.012 | -0.109 | -1.977 | -0.398 | -8.446 |
Capital Expenditures | -4.326 | -0.023 | -0.77 | -0.398 | -1.954 |
Other Investing Cash Flow Items, Total | -0.686 | -0.086 | -1.207 | -6.492 | |
Cash From Financing Activities | -33.855 | -119.966 | -18.447 | -9.394 | -24.095 |
Total Cash Dividends Paid | -31.729 | -118.981 | -19.141 | -9.9 | -25.042 |
Issuance (Retirement) of Debt, Net | -2.126 | -0.985 | -2.106 | -1.094 | -1.563 |
Net Change in Cash | -1.576 | 1.582 | 2.734 | 1.515 | -1.268 |
Financing Cash Flow Items | 0 | 0 | 2.8 | 1.6 | 2.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
TalkMed Company profile
About TalkMed Group Ltd
TalkMed Group Limited is a Singapore-based investment holding company. The Company’s Oncology services segment is engaged in the provision of oncology services to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., Thu Cuc International General Hospital in Hanoi, Vietnam and Hong Kong Integrated Oncology Centre Holdings Limited. The Company has expanded its oncology services to China. Its Stem cell related products and services segment is engaged in the provision of services related to processing, culturing and storage of stem cells through its subsidiary, Stem Med Pte. Ltd. (Stem Med) to Parkway Cancer Centre, a division of Parkway Hospitals Singapore Pte. Ltd., StemCord Pte Ltd, the non-controlling shareholder of Stem Med and other individual customers. The Cellular and gene therapy related products and services segment is engaged in the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, TalkMed Group Ltd revenues decreased 2% to SP$60.7M. Net income increased 10% to SP$25.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income reflects Impairment loss decrease from SP$3.4M (expense) to SP$0K, Cost of share-based payments to employee decrease of 76% to SP$512K (expense).
Industry: | Healthcare Facilities & Services (NEC) |
101 Thomson Road
#09-02 United Square
307591
SG
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com